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Abstract
Background: Renal cell carcinoma (RCC) is a seventh ranked malignancy with poor prognosis. RCC is lethal at
metastatic stage as it does not respond to conventional systemic treatments, and there is an urgent need to find
out promising novel biomarkers for effective treatment. The goal of this study was to evaluate the biomarkers that
can be potential therapeutic target and predict effective inhibitors to treat the metastatic stage of RCC.
Methods: We conducted transcriptomic profiling to identify differentially expressed genes associated with RCC.
Molecular pathway analysis was done to identify the canonical pathways and their role in RCC. Tissue microarrays
(TMA) based immunohistochemical stains were used to validate the protein expression of cyclinD1 (CCND1) and were
scored semi-quantitatively from 0 to 3+ on the basis of absence or presence of staining intensity in the tumor cell.
Statistical analysis determined the association of CCND1 expression with RCC. Molecular docking analyses were
performed to check the potential of two natural inhibitors, rutin and curcumin to bind CCND1.
Results: We detected 1490 significantly expressed genes (1034, upregulated and 456, downregulated) in RCC using
cutoff fold change 2 and p value < 0.05. Hes-related family bHLH transcription factor with YRPW motif 1 (HEY1),
neuropilin 2 (NRP2), lymphoid enhancer-binding factor 1 (LEF1), and histone cluster 1 H3h (HIST1H3H) were most
upregulated while aldolase B, fructose-bisphosphate (ALDOB), solute carrier family 12 (SLC12A1), calbindin 1 (CALB1)
were the most down regulated genes in our dataset. Functional analysis revealed Wnt/β-catenin signaling as the
significantly activated canonical pathway (z score = 2.53) involving cyclin D1 (CCND1). CCND1 was overexpressed in
transcriptomic studies (FC = 2.26, p value = 0.0047) and TMA results also showed the positive expression of CCND1 in
53 % (73/139) of RCC cases. The ligands – rutin and curcumin bounded with CCND1 with good affinity.
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Conclusion: CCND1 was one of the important upregulated gene identified in microarray and validated by TMA.
Docking study showed that CCND1 may act as a potential therapeutic target and its inhibition could focus on the
migratory, invasive, and metastatic potential of RCC. Further in vivo and in vitro molecular studies are needed to
investigate the therapeutic target potential of CCND1 for RCC treatment.
Keywords: Renal cell carcinoma, Cyclin D1, Gene expression profiling, Tissue microarray, Molecular docking,
Therapeutic target, Saudi Arabia
Background
Renal Cell carcinoma (RCC) is a major health problem
and accounts for approximately 1.5 percent of all cancer
deaths [1, 2]. It accounts for about 3 % of all cancers
and 2-3 % per year increase in global incidence [1, 3].
For RCC treatment, surgery is the best option at advance
stage, however, one third of patients develop metastases
even after surgery [4]. At metastatic stage, prognosis is
very poor because RCC patients hardly respond to con-
ventional existing systemic treatments and leads to death
[5]. RCC treatment is a big challenge without identifica-
tion of new drug targets and effective remedies. Although
previous studies have reported role of gene alterations,
their expression and deregulation of molecular signals to
be linked with cancer initiation and progression, there still
lack of curative therapy for RCC [6–8]. Therefore, identifi-
cation of a potential drug target and prediction of suitable
ligand is crucial for the patients with RCC.
The cyclin D members (D1, D2 and D3) bind to CDKs
and are required for the hematopoietic cells proliferation
and survival and perform a rate-limiting antiapoptotic
function in vivo [9]. Cyclin D1 (CCND1) overexpression
is predominantly correlated with early cancer onset, tumor
progression, shorter cancer patient survival and increased
metastases [10–12]. Induction of vascular endothelial
growth factor (VEGF) production by CCND1 promotes
oncogenesis by increasing growth and angiogenesis, while
downregulation of death receptor, Fas by CCND1 causes
chemotherapeutic and apoptosis resistance [13]. Over-
expression of CCND1 has been previously reported in
many cancers including lung cancers [14], esophageal
squamous cell carcinoma [15], head and neck cancer
[16], pancreatic cancer [17], pituitary cancer [18], and
breast cancer [19].
CCND1 is a proto-oncogene and a good biomarker for
tumor progression, found to be deregulated in several
cancers, including RCC. CCND1 along with associated
cyclins activates cyclin-dependent kinases (CDKs) - CDK4
and CDK6. G1-S phase transition during cell cycle, re-
quires phosphorylation of retinoblastoma (Rb) by CDK4
and CDK6. Hyperphosphorylation of Rb allows expression
of genes involved in DNA replication and cell division
[20–23]. The ability of CCND1 to exhibit oncogenic prop-
erty and to regulate a critical G1-S transition checkpoint
by activating CDK4/CDK6, makes it a potential thera-
peutic target of RCC [24–28].
Alternative or synergistic anticancer therapies using
natural compounds and their derivatives (polyphenols,
flavonoids, alkaloids, saponins, etc.) have been extensively
studied [29]. Rutin is a flavonol glycoside found in many
plants, including buckwheat; tobacco; asparagus, green tea
etc. and contributes to the antibacterial [30], hepatopro-
tective [31], neuroprotective [32] and antioxidant [33]
properties of the plant. It is structurally very similar to
quercitrin and has been used therapeutically to decrease
capillary fragility, to protect blood capillaries, and as ingre-
dients of multivitamin nutritional supplements and alter-
native herbal remedies. It can attach to iron ion, thereby
averting its binding to H2O2 and free radical generation.
In addition, rutin acts as an angiogenesis inhibitor and can
stall the VEGF in vitro; also has potential anticancerous
and antiproliferative property [34, 35].
Curcumin commonly known as turmeric is a phytopo-
lylphenol pigment isolated from the plant Curcuma
longa, and possesses a variety of pharmacologic properties
like anti-inflammatory, antineoplastic, antiproliferative, an-
ticancer, apoptosis inducer, chempreventive [36, 37]. It can
inhibit the reactive-oxygen species formation, cyclooxy-
genases (COX) and other metabolic enzymes involved in
inflammation; and can disrupt cell signal transduction via
inhibition of protein kinase C. It can interact with myriad
of biomolecules by covalent and non-covalent binding. The
H-bonding and hydrophobic interactions, arising from the
aromatic and tautomeric structures in addition to the flex-
ible linker group owe for the non-covalent interactions
[38]. Curcumin reportedly suppress cyclin D1 expression
by promoting proteolysis and down-regulating its expres-
sion and causes inhibition of CDK4-mediated phosphoryl-
ation of retinoblastoma protein [39]. It has been reported
that curcumin-treated cells show decreased expression of
CCND1, resulting in low cell growth rate. This curcumin-
induced CCND1 mRNA down-regulation is perhaps
mediated by induction of BTG2 as well as inhibition of
nuclear translocation of NF-kappaB [40].
In this study, expression profiling of RCC (CEGMR
data) identified 1490 significantly differentially expressed
genes and molecular pathway analysis predicted alteration
in many important cancer related pathways. However, the
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major finding of this study was identification and tissue
microarray based validation of CCND1 as important over-
expressed gene/proteins of RCC. Overexpression of
CCND1 can trigger cancer by activating many pathways,
including Wnt/β-catenin signaling pathway and has been
shown to exhibit oncogenic property, making it a potential
therapeutic target. We, therefore, attempted docking study
to show the therapeutic potential of anticancerous natural
ligands (rutin and curcumin) against the identified poten-
tial drug target (CCND1).
Methods
Patients and samples
The study was executed on RCC patients from Saudi
Arabia and resected tissue samples were collected from
collaborating hospitals of Jeddah during the period 2010–
2014. For gene expression analysis, fresh surgically resected
tumor and normal tissue were collected and stored in
RNALater (Invitrogen/Life Technologies, NY, USA) till
RNA extraction. All patients included in the present
study were Saudi in origin and diagnosed with clear cell
or chromophobe renal cell carcinoma without any prior
chemotherapy or radiotherapy exposure.
Ethical approval
Local ethical committee has approved this study (08-
CEGMR-02-ETH). Patients were included in the present
study only after their prior consent.
RNA extraction and array processing
Qiagen RNeasy Mini Kit (Qiagen, Hilden, Germany) was
used to extract total RNA from fresh kidney tissue, Nano
Drop 1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA) was used for concentration de-
termination and RNA quality was checked with Bioa-
nalyzer (Agilent Technologies, CA, USA). Out of 20
specimen, only 7 tumor and 5 control samples passed
the selection criteria of RNA integrity number (RIN)
>5 and were judged fit to be used for array expression
analysis. We used Human Gene 1.0 ST GeneChip arrays
(Affymetrix, Santa Clara, CA, USA) for transcriptomics
studies (Life Technology, Grand Island, NY), interrogating
764,885 probes and 36,079 annotated reference sequences
(NCBI build 36). We processed 250 ng RNA of 12 samples
using the Ambion WT Expression Kit (Life Technologies,
Austin, TX), GeneChip Hybridization, Wash and Stain Kit
(Affymetrix, Santa Clara, CA) and GeneChip WT Ter-
minal Labeling and Controls Kit (Affymetrix, Santa Clara,
CA). The hybridization of 5500 ng of cDNA was done in a
hybridization oven at 45 °C under rotation (60 rpm) for
17 h. After complete processing, the arrays were scanned
in the GeneChip Scanner 3000 7G and GeneChip Com-
mand Console Software (AGCC) were used to generate
probe cell intensity data (CEL files).
Gene expression analysis
We carried transcriptomic profiling of 12 samples, seven
RCC and five normal kidney tissues. To gain confidence
with our limited number samples, we performed a com-
parative analysis with independent expression datasets
from NCBI’s GEO database (GSE781, n = 34; GSE7023,
n = 47; and GSE6344, n = 40) for confirmation. Affyme-
trix. CEL files were imported and analyzed using Partek
Genomics Suite version 6.6 (Partek Inc., MO, USA). De-
fault settings robust multi-chip averaged (RMA) was
used to log-transform data set and for normalization.
Analysis of Variance (ANOVA) was applied, and differ-
entially expressed genes (DEGs) were identified with cut
off fold change > 2 and p value <0.05. Principal component
analysis (PCA) was performed to assess overall expression
pattern among sample groups, similar samples were
grouped together.
Tissue microarray and immunohistochemistry
Tissue microarrays (TMA) were designed and con-
structed for 139 primary RCC and 34 normal kidney tis-
sue as previously described [41]. Experienced pathologist
reviewed hematoxylin and eosin (HE) slides of RCC and
normal kidney tissue. 1.5 mm tissue cores from areas of
interest were chosen from donor block(s) and trans-
ferred to recipient paraffin block of TMA Master 1.14
SP3 (3D Histech Ltd, Budapest, Hungary). HE staining
of TMA slides was repeated to assess basic morphology
of slide construction.
Immunohistochemical studies were performed on
positive-charged leica plus slides (Leica Microsystems,
Wetzler, Germany) mounted with 4 μm of TMA paraffin
blocks. Deparaffinisation of sections was done using xy-
lene, followed by rehydration in an automated BenchMark
XT immunostainer (Ventana® Medical systems Inc.,
Tucson, AZ, USA) and pretreatment in prediluted cell
conditioning 1 (CC1) solution for an hour. Immunostaining
of TMA slides was done by incubating anti-CCND1 anti-
body at 37 °C for 16 min, followed by washing, counter-
staining (with Mayer’s hematoxylin) and mounting using
Ventana® Ultraview Universal DAB detection kit. For ana-
lysis and interpretation both negative (with tris-buffered sa-
line only) and positive (with primary antibody) control
slides were used. Sections were evaluated independently by
the pathologist without knowing the clinicopathological
characteristics of RCC patients. Immunostainings were
scored semiquantitatively from 0 to 4 + .
Functional and pathway analysis
We performed pathway analyses and Gene ontology
(GO) studies for differentially regulated genes in RCC to
find associated biological networks and molecular pro-
cesses, using Ingenuity Pathways Analysis (IPA) software
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(Ingenuity Systems, Redwood City, CA). Significantly
expressed genes with Affymetrix ID, expression level and
p-value were uploaded into IPA software to identify the
most significant altered biological functions and net-
works. Fisher’s exact test was used to calculate the sig-
nificance of association between trancriptomic data and
canonical pathways of RCC.
Molecular docking studies
The 3-D crystal structure of cyclin D1 was retrieved
from RCSB’s Protein Data Bank (PDB) – PDB id: 2w96:
Chain A. Structure visualization and illustration was
done using PyMol (DeLano Scientific) (Fig. 1). The mo-
lecular structure of rutin and curcumin were retrieved
from NCBI’s PubChem compound database with CID
5280805 and 969516 respectively (Fig. 2).
Molecular docking was performed using Molecular
Docking Server on [42]. The MMFF94 force field geometry
optimization method was used for energy minimization of
ligand molecule: rutin and curcumin using DockingServer.
Gasteiger partial charges were added to the ligand atoms
at pH 7.0. Non-polar hydrogen atoms were merged,
and rotatable bonds were defined. Rest methodology
was followed in sequential manner as previously de-
scribed [2, 6, 43].
Supporting data availability
Data series (Accession No. GSE781, GSE7023, GSE6344)
used in present study are available at NCBI’s Gene Ex-
pression Omnibus database (http://www.ncbi.nlm.nih.
gov/geo/).
Results
This study focused on utilizing transcriptomic profiling
to identify biomarkers associated with RCC and conducting
molecular docking analysis to assess the interactions be-
tween potential target and drugs. We identified CCND1 as
important overexpressed gene/proteins of RCC and dem-
onstrated its potential as possible anticancer drug target.
Fig. 1 Molecular structure of rutin and curcumin retrieved from
NCBI’s PubChem compound database with CID 5280805 and 969516
Fig. 2 Overall cyclin D1 structure depicted as ribbon diagram (PDB: 2 W96)
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Fig. 3 Scatter plot of PCA show grouping of similar type based on genome-wide expression values, as represented as eclipse, where each ball
represents one sample. Blue and red is representing RCC and normal kidney tissue
Fig. 4 Hierarchical clustering and functional analysis of significantly differentially expressed genes in kidney cancer using Affymetrix Human ST 1.0
array and Partek Genomics suite (ver 6.6)
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Table 1 Differentially expressed significant genes in RCC
Gene symbol Gene name RefSeq p-value Fold-change
HEY1 hes-related family bHLH transcription factor with YRPW motif 1 NM_001040708 7.88E-06 3.64128
NRP2 neuropilin 2 ENST00000272849 0.00017 3.63215
LEF1 lymphoid enhancer-binding factor 1 NM_001130713 4.04E-05 3.54448
HIST1H3H histone cluster 1, H3h NM_003536 3.29E-05 2.87948
ITGAX integrin, alpha X (complement component 3 receptor 4 subunit) NM_000887 3.23E-05 2.69367
BUB1 BUB1 mitotic checkpoint serine NM_001278616 3.35E-05 2.62163
MAP3K7CL MAP3K7 C-terminal like NM_001286620 2.81E-05 2.54523
FXYD5 FXYD domain containing ion transport regulator 5 NM_001164605 0.000158 2.45618
HIST1H2AI histone cluster 1, H2ai NM_003509 0.000108 2.27918
CENPK centromere protein K NM_001267038 6.01E-05 2.27502
CCND1 cyclin D1 NM_053056 0.004789 2.25898
DDX11 DEAD NM_001257144 0.000178 2.24119
APOBEC3D apolipoprotein B mRNA editing enzyme, catalytic polypeptide-li NM_152426 2.61E-06 2.23905
ATAD2 ATPase family, AAA domain containing 2 NM_014109 0.000129 2.18905
HIST1H3F histone cluster 1, H3f NM_021018 0.00016 2.14196
TREM2 triggering receptor expressed on myeloid cells 2 NM_018965 0.00021 2.13092
GAL3ST4 galactose-3-O-sulfotransferase 4 NM_024637 1.50E-05 2.11736
LOC400464 uncharacterized LOC400464 AK127420 9.33E-05 2.11281
CXCL11 chemokine (C-X-C motif) ligand 11 NM_005409 0.0002 2.07422
NEIL3 nei endonuclease VIII-like 3 (E. coli) NM_018248 2.73E-05 2.06874
EVL Enah ENST00000553771 5.57E-05 2.06506
SLFN12L schlafen family member 12-like ENST00000361112 9.07E-05 2.02832
ALDH4A1 aldehyde dehydrogenase 4 family, member A1 NM_001161504 4.94E-07 −16.1809
SLC22A12 solute carrier family 22 (organic anion NM_001276326 9.50E-06 −16.4997
SLC47A2 solute carrier family 47 (multidrug and toxin extrusion), me NM_001099646 5.60E-06 −17.2214
HAO2 hydroxyacid oxidase 2 (long chain) NM_001005783 0.000192 −17.3322
SLC6A19 solute carrier family 6 (neutral amino acid transporter), me NM_001003841 0.000195 −18.4585
XPNPEP2 X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound NM_003399 0.000131 −18.9386
CYP4A11 cytochrome P450, family 4, subfamily A, polypeptide 11 XR_246241 7.59E-05 −19.2237
SLC22A6 solute carrier family 22 (organic anion transporter), member 6 NM_004790 5.33E-06 −20.6522
KCNJ1 potassium inwardly-rectifying channel, subfamily J, member 1 NM_000220 8.79E-05 −22.4359
TMEM52B transmembrane protein 52B NM_001079815 0.000112 −23.1374
SLC12A3 solute carrier family 12 (sodium NM_000339 1.14E-06 −27.7638
HPD 4-hydroxyphenylpyruvate dioxygenase NM_001171993 1.88E-05 −29.7949
SLC5A12 solute carrier family 5 (sodium XM_006718157 0.000155 −30.9613
KNG1 kininogen 1 NM_000893 4.28E-06 −34.7144
SLC13A3 solute carrier family 13 (sodium-dependent dicarboxylate tra NM_001011554 1.93E-06 −37.6483
SLC36A2 solute carrier family 36 (proton NM_181776 4.06E-07 −37.8957
PLG plasminogen NM_000301 4.87E-07 −43.0535
SLC22A8 solute carrier family 22 (organic anion transporter), member NM_001184732 4.50E-06 −45.8474
UMOD uromodulin NM_001008389 2.44E-06 −68.9599
CALB1 calbindin 1, 28 kDa NM_004929 2.29E-06 −78.3947
SLC12A1 solute carrier family 12 ENST00000330289 0.000135 −79.6698
ALDOB aldolase B, fructose-bisphosphate NM_000035 2.56E-05 −87.9122
Negative fold change value indicates the downregulation
*bold data shows CCND1 (Cyclin D1) was overexpressed (fold change = 2.258) and statistically significant (p-value = 0.00478)
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Identification of differentially expressed genes
Three-dimensional scatter plot of PCA demonstrated
that RCC and control tissues are distinctly clustered
(Fig. 3). We did genome-wide transcription profiling of
fresh RCC specimens and identified 1490 differentially
expressed genes; 1034 up-regulated and 456 down-
regulated using unadjusted p value < 0.05 (Additional file
1). Number of differentially expressed genes reduced to
141 (22 up-regulated and 119 down regulated) on applying
the stringent condition of false discovery rate with p value
< 0.05 while keeping all other above parameter same
(Fig. 4, Table 1). Hes-related family bHLH transcription
factor with YRPW motif 1 (HEY1), neuropilin 2 (NRP2),
lymphoid enhancer-binding factor 1 (LEF1), and histone
cluster 1 H3h (HIST1H3H) were the most upregulated
ones while aldolase B, fructose-bisphosphate (ALDOB),
solute carrier family 12 (SLC12A1), calbindin 1 (CALB1)
were the most down regulated genes in our dataset. We
compared our identified differentially expressed genes list
with re-analyzed GEO data series (GSE781, GSE6344 and
GSE7023) and identified over-expression of CCND1 in all
dataset, thus supporting our result (Table 2).
Validation of CCND1
Transcriptomic profiling revealed distinct CCND1 over-
expression (FC = 2.26, p value = 0.0047). Validation study
based on TMA-immunohistochemistry staining showed
the positive expression of CCND1 in 53 % (73/139) of
RCC cases (Fig. 5).
Pathways and networks underlying RCC
Pathway analysis of identified DEGs revealed the bio-
functions, molecular network and canonical pathways
association with RCC (Table 3). Most significantly
inhibited pathways were synaptic long term potenti-
ation (z-score = −2.33), NRF2-mediated oxidative stress
response (z-score = −2.33), production of nitric oxide and
reactive oxygen species in macrophages (z-score = −2.324),
and renin-angiotensin signaling (z-score = −2.121). Wnt/
β-catenin signaling was significantly activated pathway
(z-score = 2.53) involving following genes; cyclin D1
(CCND1, FC = 2.26), CD44 molecule (CD44, FC = 2.31),
v-myc avian myelocytomatosis viral oncogene homolog
(c-Myc, FC = 2.31), HNF1 homeobox A (TCF1, FC =−2.26),
secreted frizzled-related protein 1 (SFRP1, FC = −4.45)
(Fig. 6). We found over expression of CCND1 playing
important role in regulation of Wnt/β-catenin signaling
along with other cancer related pathways like Acute
Myeloid Leukemia Signaling, Non-Small Cell Lung
Cancer Signaling, PTEN Signaling, Regulation of Cellular
Mechanics by Calpain Protease, ErbB2-ErbB3 Signaling,
HER-2 Signaling in Breast Cancer, HER-2 Signaling in
Breast Cancer, Thyroid Cancer Signaling, Endometrial
Cancer Signaling etc. Further extensive molecular pathway
analysis may help to better understand the mechanism of
RCC initiation, invasion and metastasis.
Docking studies
We made a structural attempt to study possible binding
of two natural famed ligands with the potential thera-
peutic drug target, Cyclin D1 for cancer therapeutics.
CCND1 protein has a classical double cyclin box domain
fold, comprising of 11 alpha-helices [44].
Molecular docking studies predicted good interactions
between three dimensional structure of drug target
(CCND1, PDBID: 2w96) and selected ligands; rutin and
curcumin. Molecular docking revealed that both the
compounds are able to bind in the ligand binding do-
main. In silico docking studies revealed interaction of
two active compounds with the common vital ligand
binding site residues (Leu91, Lys149, Asn151) of cyclin
D1. Both rutin and curcumin docked at a common lig-
and binding site of CCND1 slightly varied intensity as
estimated by their size, structure, stereochemistry (Figs. 7
and 8; Table 4). We also examined their complete
interaction profile including hydrogen bonds, HB plot,
polar, hydrophobic, pi-pi and cation-pi interactions.
The estimated free energy of binding with Cyclin D1 for
rutin was −4.26 kcal/mol and for curcumin was −4.67 kcal/
mol which is very similar, however, the estimated inhibition
constant (Ki) was 757.57 μM and 380.02 μM respectively.
Table 2 Expression of CCND1 in Saudi RCC patients (CEGMR
dataset) and GEO dataset
Dataset Sample size P-value Fold change
CEGMR (own data) 12 0.0047 2.26
GSE781 34 0.0030 2.41
GSE6344 40 1.04 × 10−9 4.82
GSE7023 47 6.55 × 10−5 3.33
Fig. 5 Immunohistochemistry stain for CCND1 show positive
staining in RCC (original magnification × 60)
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Discussion
RCC is a complex heterogeneous tumors involving altered
genes and proteins. We performed a transcriptional profiling
and functional analysis of RCC to understand the role of
identified significant genes in regulation of physiological
processes through biological pathways/networks. We
Table 3 Canonical pathways predicted by Ingenuity Pathway Analysis for significant genes differentially expressed in kidney cancer
Ingenuity canonical pathways -log
(p-value)
z-score Molecules
Wnt/β-catenin Signaling 0.271 2.530 CSNK1E,MYC,PPP2R4,TGFBR3,CD44,LEF1,SFRP1,UBC,CCND1,HNF1A,ACVR2A,LRP1





Production of Nitric Oxide and Reactive
Oxygen Species in Macrophages
0.512 −2.324 PPARA,MAP3K15,APOE,APOM,PPP1R3C,PRKCZ,APOL1,ALB,PPP2R4,CYBA,APOC1,
CHUK,APOD,RBP4,PRKCA
Sperm Motility 1.19 −2.309 PLA2G16,SLC16A10,PLCB4,PLA2R1,PRKAR2A,PNPLA3,PLCL1,PLA2G12B,PDE1A,
PLCD4,PLA2G7,PRKCZ,PRKCA
Renin-Angiotensin Signaling 0.279 −2.121 ADCY9,GRB2,REN,PRKAR2A,CCL5,PRKCZ,AGT,PRKCA
Nitric Oxide Signaling in the
Cardiovascular System
0.27 −1.890 KNG1,CAV1,PRKAR2A,CACNA1C,PDE1A,PRKCZ,PRKCA
Antioxidant Action of Vitamin C 3.01 1.897 PLA2G16,NAPEPLD,PLA2R1,SLC23A3,PLA2G7,GLRX,SLC2A3,PLCB4,SLC23A1,SLC2A2,
PNPLA3,CHUK,TXN,PLA2G12B,PLCL1,PLCD4
Aldosterone Signaling in Epithelial Cells 1.34 −1.897 DNAJC12,DNAJC19,PDPK1,HSPD1,HSPA2,PRKCZ,HSPA12A,DNAJC11,PLCB4,SCNN1G,
SLC12A1,CRYAA/LOC102724652,SCNN1B,PLCL1,PLCD4,PRKCA,AHCY
Valine Degradation I 10.11 NaN ECHS1,ABAT,ACADSB,BCKDHB,BCAT1,HIBCH,HIBADH,AUH,DLD,DBT,EHHADH,
HADHA,ALDH6A1
Ethanol Degradation II 9.4 NaN HSD17B10,ADH6,ALDH1B1,ALDH4A1,ACSS1,ALDH9A1,ADH5,ALDH2,AKR1A1,ALDH3A2,
ACSS2,ADHFE1,ACSL1,ALDH7A1,DHRS4
Fatty Acid β-oxidation I 9.4 NaN HSD17B10,ECHS1,SLC27A2,ACAA1,ACAA2,SCP2,ECI2,AUH,ACSL4,IVD,EHHADH,ACADM,
HADHA,ACSL1,HADH
FXR/RXR Activation 9.17 NaN PPARA,KNG1,APOE,PKLR,APOH,ABCC2,SLC22A7,HNF1A,CYP8B1,MTTP,PCK2,SCARB1,
SLC10A2,FGFR4,LPL,GC,AGT,APOM,SDC1,UGT2B4,CYP27A1,SERPINF2,APOL1,ALB,
FABP6,APOC1,FBP1,G6PC,SLC51B,RBP4,APOD






Tryptophan Degradation 7.34 NaN ALDH4A1,ALDH1B1,ALDH2,AKR1A1,SMOX,ALDH3A2,DDC,ALDH9A1,ALDH7A1,MAOA
PXR/RXR Activation 4.04 NaN PPARA,SCD,GSTM1,ABCB1,ABCC2,PRKAR2A,CES2,HMGCS2,UGT1A1,PCK2,ALDH3A2,
GSTA1,G6PC,CYP2B6
Acute Myeloid Leukemia Signaling 0.491 0.816 RUNX1,MYC,GRB2,LEF1,CCND1,HNF1A,IDH1
Non-Small Cell Lung Cancer Signaling 0.481 −0.816 GRB2,PDPK1,EGF,ERBB2,CCND1,PRKCA
PTEN Signaling 0.662 0.905 FGFR3,GRB2,FGFR4,TGFBR3,PREX2,ITGA5,FGFR2,PDPK1,CHUK,CCND1,PRKCZ
Regulation of Cellular Mechanics by
Calpain Protease
0.453 −1.000 GRB2,ITGA5,EGF,CCND1,ACTN1
ErbB2-ErbB3 Signaling 0.967 −1.890 MYC,GRB2,NRG3,PDPK1,ERBB3,ERBB2,CCND1
Aryl Hydrocarbon Receptor Signaling 2.07 NaN GSTA3,GSTM1,ALDH4A1,ALDH1B1,GSTM3,NQO2,NQO1,ALDH8A1,CCND1,ALDH9A1,
MYC,ALDH1L1,ALDH1L2,ALDH3A2,GSTA1,ALDH5A1,ALDH6A1,ALDH7A1
HER-2 Signaling in Breast Cancer 1.01 NaN GRB2,PARD6B,EGF,ERBB3,ITGB8,ERBB2,CCND1,PRKCZ,PRKCA
Thyroid Cancer Signaling 0.828 NaN CXCL10,MYC,LEF1,CCND1,HNF1A
Endometrial Cancer Signaling 0.765 NaN MYC,GRB2,PDPK1,LEF1,ERBB2,CCND1
Role of Macrophages, Fibroblasts and




Estrogen-mediated S-phase Entry 0.278 NaN MYC,CCND1
*bold data shows presence and importance of CCND1 among identified canonical pathways
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found CCND1 as one of the significantly expressed
gene and potential biomarker RCC.
HEY1, an upregulated gene, has been reported to be
mediator of notch signaling, showing pro-oncogenic
function and promotes cancer progression [45, 46].
Neuropilin-2 (Nrp2) is a well known receptor for the
vascular endothelial growth factor-C (VEGF-C) and acti-
vates lymph nodes as well as promotes tumor metastasis
by lymphangiogenesis [47, 48]. LEF1 interacts with β-
catenin and plays critical role in proliferation of RCC
by activating downstream target genes [49, 50]. Wnt/
β-catenin signaling, found activated, regulates embryonic
development and is involved in many diseases including
cancer, polycystic kidney disease [51–54]. WNT signal and
its paracrine mode to growth of cancer cells makes it clin-
ically important to understand the metastasis of tumor
Fig. 6 Wnt-β catenin signaling was significantly activated (z-score = 2.53) in RCC based on following differentially expressed genes: cyclin D1
(CCND1, FC = 2.25898), CD44 molecule (CD44, FC = 2.31667), v-myc avian myelocytomatosis viral oncogene homolog (c-Myc, FC = 2.31324),
HNF1 homeobox A (TCF1, FC = −2.26661), secreted frizzled-related protein 1 (SFRP1, FC = −4.45838). Red represents overexpression and
green underexpression
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cells [53, 55, 56]. HIST1H3H is frequently altered
chromatin factors in many cancers [57, 58]. Aldolase,
a family member of glycolysis enzymes, was found to
be significantly affecting RCC. Aldolase-A was report-
edly upregulated while aldolase-B was downregulated
in RCC and human primary hepatocellular carcinoma
[59–62]. SLC12 family members are involved in regu-
lation of cell volume, blood pressure and chloride con-
centration, and play a critical role in diseases like
cancer, epilepsy and osteoporosis [63]. In the present
study, SLC12 was down regulated that is in accord-
ance to other findings [64]. CALB1 is reported to be
Fig. 7 Molecular docking conformation and interactions of rutin and curcumin with Cyclin D1
Fig. 8 Two-dimensional plot showing the primary interacting residues of Cyclin D1
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altered in RCC and found to be negatively stained
compared to normal tissue [61, 65].
CCND1 was overexpressed in our as well as other
transcriptomics studies [66–69]. We validated CCND1
overexpression by using tissue microarray platform
and in silico docking analysis was done to check its
therapeutic potential as it plays a key role in G1-S
phase transition of cell cycle. There are reports of anti-
proliferative, apoptosis inducing and chemopreventive
effects of natural bioactive flavonoids like baicalein,
catechin, genistein, quercetin, and rutin. Docking analysis
showed that rutin and curcumin binds to CCND1 and
can potentially inhibit downstream CCND1/CDK4/CDK6
complex formation, required for G1-S phase transition.
Our finding demonstrate the anticancer drug targets
potential of CCND1 and rutin and curcumin as poten-
tial inhibitors, however, this in silico docking study has
to be validated further.
Conclusion
Our microarray and immunohistochemistry results sug-
gest significantly high levels of cyclin D1 expression in
RCC. Distinct transcriptomic signatures identified for
RCC needs verification at larger dataset and additional
significant genes need to be further validated for iden-
tification of novel biomarkers. The critical role of
CCND1 in RCC metastasis by activating G1-S transi-
tion of cell cycle has drawn our attention to examine
its potential as anticancer drug target. Our in silico
docking study shown CCND1 protein as an attractive
anticancer target and natural flavanoids rutin and cur-
cumin as potential anticancer drug of RCC and they
may be promising in the prevention of kidney cancer
too. Quantitative structure-activity relationship studies,
ligand binding, efficacy and toxicity should be further in-
vestigated before clinical trials. Clinical and therapeutic
applications of these natural ligands were initially limited
by their low solubility and bioavailability but combination
with adjuvant and nano-technology based delivery vehicles
can immensely improve their potential. Moreover, these
are reported to act in synergism with several other natural
compounds or synthetic agents routinely used in chemo-
therapy and can assist in cancer prevention and treatment
when used alone or in combination with other conven-
tional treatments.
Additional file
Additional file 1: Differentially expressed genes of RCC from Saudi
patients on comparing RCC with normal kidney tissue. Transcriptomics
profiling revealed 1490 differentially expressed genes, 1034 up-regulated
and 456 down-regulated, with fold change ≥ 2 and p-value < 0.05.
(XLSX 209 kb)
Acknowledgment
This project and publication was supported by the NSTIP strategic
technologies program in the Kingdom of Saudi Arabia – Project No
(10-BIO1258-03, 09-BIO1073-03, 08-MED120-03). The authors also
acknowledge with thanks Science and Technology Unit, King Abdulaziz
University for technical support. Authors would like to acknowledge the
Deanship of Scientific Studies, King Abdulaziz University, Jeddah, Saudi
Arabia for funding the research (HiCi-1434-117-2). We also thank the
patients, physicians, nurses, and pathologists of the King Abdulaziz
University Hospital, and King Faisal Specialist Hospital and Research
Center, Jeddah, Saudi Arabia.
Declaration
This article has been published as part of BMC Cancer Volume 16
Supplement 2, 2016: Proceedings of the 3rd International Genomic Medicine
Conference: cancer. The full contents of the supplement are available online
at http://bmccancer.biomedcentral.com/articles/supplements/volume-16-
supplement-2.
Availability of data and material
Data series (Accession No. GSE781, GSE7023, GSE6344) used in present
study are available atNCBI’s Gene Expression Omnibus database
(http://www.ncbi.nlm.nih.gov/geo/).
Authors’ contributions
SK, JM and HF participated in the study design. HJS, AAA, FA and MS
performed data collection, DNA extraction and microarray studies. AB and
JM did tissue microarray, immunohistochemistry and pathological studies.
SK, ZM and HN analyzed data, interpreted the results and drafted the manuscript.
KA, AMA, AC, AS and MHQ participated in critical review, editing and finalization
of manuscript. All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Ethical approval
Local ethical committee has approved this study (08-CEGMR-02-ETH).
Patients were included in the present study only after their prior consent.
Ethical approval information is included in the materials and methods
section. Local ethical committee has approved this study under the approval
number 08-CEGMR-02-ETH.
Consent for publication
Patients’ consent information are included in the material and methods
section. Patients were only included in the present study after their prior
consent.
Author details
1Center of Excellence in Genomic Medicine Research, Faculty of Applied
Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
2Department of Pathology, King Abdulaziz University, Jeddah, Saudi Arabia.
3Department of Pathology, King Faisal Specialist Hospital and Research
Center, Jeddah, Saudi Arabia. 4Department of Urology, Faculty of Medicine,
King Abdulaziz University, Jeddah, Saudi Arabia. 5King Fahd Medical Research
Center, King Abdulaziz University, Jeddah, Saudi Arabia. 6Department of
Otorhinolaryngology and Head and Neck Surgery, King Abdulaziz University,
Jeddah, Saudi Arabia. 7KACST Innovation Center for Personalized Medicine,
King Abdulaziz University, Jeddah, Saudi Arabia.
Table 4 Docking features and values for rutin and curcumin
Features RUTIN CURCUMIN
Est. Free energy of binding −4.26 kcal/mol −4.67 kcal/mol
Est. Inhibition Constant, Ki 757.57 μM 380.02 μM
vdW+ Hbond + desolv Energy −5.43 kcal/mol −6.37 kcal/mol
Electrostatic energy −0.01 kcal/mol −0.12 kcal/mol
Total intermolecular energy −5.44 kcal/mol −6.49 kcal/mol
Interaction surface 653.668 684.416
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